ALX Oncology Holdings Inc reports results for the quarter ended in March - Earnings Summary

ALX Oncology Holdings

11/05/2023 22:16

* ALX Oncology Holdings Inc  ALXO.OQ  reported a quarterly
adjusted loss of 74 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 80 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ALX Oncology Holdings Inc's reported EPS for the quarter
was a
loss of 74 cents​.
    * The mean earnings estimate of analysts had risen by
about 13% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * ALX Oncology Holdings Inc shares had risen by 43.6% this
quarter and lost 42.4% so far this year.
    * The company reported a quarterly loss of $30.18 million.
    * Wall Street's median 12-month price target for ALX
Oncology
Holdings Inc is $29.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:16 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.80          -0.74          Beat
 Dec. 31 2022      -0.89          -0.75          Beat
 Sep. 30 2022      -0.77          -0.87          Missed
 Jun. 30 2022      -0.63          -0.81          Missed